| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8819912 | Respiratory Medicine | 2018 | 7 Pages |
Abstract
The magnitude of bronchodilatory effect was similar with and without a VHC following GFF MDI treatment. This, together with the PK and safety profiles, supports the use of the VHC with GFF MDI for the maintenance treatment of COPD, which could be particularly useful for patients who have difficulty with the coordination of an MDI.
Keywords
MDItmaxICSCminPEFRAUC0–12FVCvHCFDCGFFCFCLLQValved holding chamberFormoterol fumarate dihydrateCmaxFEV1HFAmITTLAMATEAElong-acting muscarinic antagonistLong-acting β2-agonistmodified intent-to-treatstandard deviationITTCOPDChronic obstructive pulmonary diseaseanalysis of varianceANOVAFixed-dose combinationRandomizationforced expiratory volume in 1 slower limit of quantificationpeak expiratory flow ratemaximum observed plasma concentrationstandard errorNot availableMetered Dose InhalerGastrointestinalLSMLABAbody mass indexBMICoefficient of Variationforced vital capacityadverse eventtreatment-emergent adverse eventPharmacokineticsSpacerconfidence intervalCo-suspension delivery technologyIntent-to-treatLeast squares meanHydrofluoroalkaneschlorofluorocarbonInhaled corticosteroidGlycopyrronium
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Faisal Fakih, Selwyn Spangenthal, Barry Sigal, Patrick Darken, Andrea Maes, Shahid Siddiqui, Michael Gillen, Colin Reisner, Ubaldo J. Martin,